Abstract
During the past decade, trials for Hodgkin’s disease in adult patients carried out at the Milan Cancer Institute mainly focused on the development and evaluation of non-cross-resistant drug regimens [1]. This approach was based on the limitations of MOPP and MOPP-derived regimens in achieving cure in Stage III and IV Hodgkin’s disease as well as on the low salvage rate observed with retreatment in complete responders relapsing within 12 months from first complete remission (CR). Both events were attributed to selective resistance to two or more drugs in a single multidrug combination [2, 3]. An additional trial was specifically designed to compare iatrogenic effects resulting from regimens with (MOPP) and without (ABVD) alkylating agents and procarbazine. These drugs are responsible for inducing sterility and cancerogenesis [1, 4].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bonadonna G (1982). Chemotherapy strategies to improve the control of Hodgkin’s disease. The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 42: 4309–4320.
Skipper HE and Schabel FM Jr. (1984). Tumor stem cell heterogeneity: Implications with respect to classification of cancers by chemotherapeutic effect. Cancer Treat Rep 68: 4361.
Skipper HE and Schabel FM Jr. (1984). Tumor stem cell heterogeneity: Implications with respect to classification of cancers by chemotherapeutic effect. Cancer Treat Rep 68: 4361.
Bonadonna G, Santoro A (1983). Drug selection in the treatment of Hodgkin’s disease. Haematol Oncol 1: 3–12.
Bonadonna G and Santoro A (1982). ABVD chemotherapy in the treatment of Hodgkin’s disease. Cancer Treat Rev 9: 21–35.
Bonadonna G, Santoro A, Bonfante V and Valagussa P (1982). Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin’s disease: Rationale, background studies, and recent results. Cancer Treat Rep 66: 881–887.
Santoro A, Bonfante V and Bonadonna G (1982). Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin’s disease. Ann Intern Med 96: 139–143.
Santoro A, Bonadonna G, Bonfante V and Valagussa P (1982). Alternating drug combinations in the treatment of advanced Hodgkin’s disease. N Engl J Med 306: 770–775.
Valagussa P, Santoro A, Fossati-Bellani F et al. (1982). Absence of treatment-induced second neoplasms after ABVD in Hodgkin’s disease. Blood 3: 488–494.
Santoro A, Bonfante V, Viviani S et al. (1984). Salvage chemotherapy in relapsing Hodgkin’s disease. Proc Amer Soc Clin Oncol 3: 254.
Bonadonna G, Viviani S, Bonfante V et al. (1984). Alternating chemotherapy with MOPP/ABVD in Hodgkin’s disease: Updated results. Proc Amer Soc Clin Oncol 3: 254.
Viviani S, Santoro A, Ragni G et al. (1984). Gonadal toxicity after combination chemotherapy for Hodgkin’s disease. Comparative results of MOPP versus ABVD. (In press).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Bonadonna, G. et al. (1985). Current status of the Milan trials for Hodgkin’s disease in adults. In: Cavalli, F., Bonadonna, G., Rozencweig, M. (eds) Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances. Developments in Oncology, vol 32. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2607-6_31
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2607-6_31
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9632-4
Online ISBN: 978-1-4613-2607-6
eBook Packages: Springer Book Archive